Patents by Inventor Takayoshi Fukushima

Takayoshi Fukushima has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240242814
    Abstract: The present invention addresses the problem of providing a method that enables more accurate suggestions for improving both the health and beauty conditions of a user. A second acquisition unit 121 acquires the user's gut bacteria data. A score determination unit 122 determines a score that indicates the health level of the gut microbiome of the user on the basis of the gut bacteria data. A type determination unit 123 determines the type to which the user's gut flora applies, among a plurality of enterotypes, on the basis of the gut bacteria data. An information unit 125 informs suggestions for improving the user's health condition to the user on the basis of the user's score and type. The problem is solved thereby.
    Type: Application
    Filed: March 23, 2022
    Publication date: July 18, 2024
    Applicant: CYKINSO, INC.
    Inventors: Yu SAWAI, Satoshi WATANABE, Takayoshi FUKUSHIMA, Yusuke MATSUO
  • Publication number: 20240092890
    Abstract: A bispecific antibody including a first domain which specifically binds to a mutant calreticulin protein and a second domain which specifically binds to a CD3 antigen. A pharmaceutical composition including the bispecific antibody or a functional fragment thereof. A diagnostic method for a myeloproliferative neoplasm, including detecting a polypeptide in a biological sample with the bispecific antibody.
    Type: Application
    Filed: August 26, 2021
    Publication date: March 21, 2024
    Applicants: JUNTENDO EDUCATIONAL FOUNDATION, MEIJI SEIKA PHARMA CO., LTD.
    Inventors: Norio KOMATSU, Marito ARAKI, Yoshihiko KIHARA, Yoji ISHIDA, Koichi KITAMURA, Takayoshi FUKUSHIMA, Kaori YASUI
  • Publication number: 20160367585
    Abstract: The present invention relates to novel aminoglycoside antibiotics, a process for producing the same, and pharmaceutical use thereof. More specifically, the present invention relates to compounds represented by formula (I), a process for producing the same, and use of the same as antimicrobial agents. wherein R represents amino or hydroxyl.
    Type: Application
    Filed: September 6, 2016
    Publication date: December 22, 2016
    Inventors: Naomi SUMIDA, Koji YANAI, Masato TANI, Takayoshi FUKUSHIMA, Yasumasa OTA, Shuichi GOMI, Akitaka NAKANE
  • Patent number: 9512409
    Abstract: An object is to efficiently produce thermostable catalase at low cost by expressing it as a recombinant protein in large quantity. A recombinant microorganism capable of efficiently expressing thermostable catalase can be provided by obtaining a DNA necessary for efficiently producing it as a recombinant protein, and the thermostable catalase can be efficiently produced at low cost by cultivating the obtained recombinant microorganism. Hydrogen peroxide can be efficiently decomposed at low cost, even at high temperature, by treating a solution containing hydrogen peroxide with the thermostable catalase of the present invention.
    Type: Grant
    Filed: January 27, 2015
    Date of Patent: December 6, 2016
    Assignee: MEIJI SEIKA PHARMA CO., LTD.
    Inventors: Kaoru Okakura, Fusuke Mazuka, Takayoshi Fukushima, Koichiro Murashima
  • Patent number: 9469863
    Abstract: The present invention relates to novel aminoglycoside antibiotics, a process for producing the same, and pharmaceutical use thereof. More specifically, the present invention relates to compounds represented by formula (I), a process for producing the same, and use of the same as antimicrobial agents. wherein R represents amino or hydroxyl.
    Type: Grant
    Filed: December 1, 2008
    Date of Patent: October 18, 2016
    Assignee: MEIJI SEIKA KAISHA, LTD.
    Inventors: Naomi Sumida, Koji Yanai, Masato Tani, Takayoshi Fukushima, Yasumasa Ota, Shuichi Gomi, Akitaka Nakane
  • Publication number: 20150132820
    Abstract: An object is to efficiently produce thermostable catalase at low cost by expressing it as a recombinant protein in large quantity. A recombinant microorganism capable of efficiently expressing thermostable catalase can be provided by obtaining a DNA necessary for efficiently producing it as a recombinant protein, and the thermostable catalase can be efficiently produced at low cost by cultivating the obtained recombinant microorganism. Hydrogen peroxide can be efficiently decomposed at low cost, even at high temperature, by treating a solution containing hydrogen peroxide with the thermostable catalase of the present invention.
    Type: Application
    Filed: January 27, 2015
    Publication date: May 14, 2015
    Applicant: MEIJI SEIKA PHARMA CO., LTD.
    Inventors: Kaoru OKAKURA, Fusuke MAZUKA, Takayoshi FUKUSHIMA, Koichiro MURASHIMA
  • Patent number: 8975053
    Abstract: An object is to efficiently produce thermostable catalase at low cost by expressing it as a recombinant protein in large quantity. A recombinant microorganism capable of efficiently expressing thermostable catalase can be provided by obtaining a DNA necessary for efficiently producing it as a recombinant protein, and the thermostable catalase can be efficiently produced at low cost by cultivating the obtained recombinant microorganism. Hydrogen peroxide can be efficiently decomposed at low cost, even at high temperature, by treating a solution containing hydrogen peroxide with the thermostable catalase of the present invention.
    Type: Grant
    Filed: February 18, 2009
    Date of Patent: March 10, 2015
    Assignee: Meiji Seika Pharma Co., Ltd.
    Inventors: Kaoru Okakura, Fusuke Mazuka, Takayoshi Fukushima, Koichiro Murashima
  • Patent number: 8697409
    Abstract: Disclosed are a ketoreductase mutant which can be used for an efficient production of daunorubicin derivatives, a DNA encoding the mutant, a transformant prepared by introducing the DNA thereinto to produce a daunorubicin derivative, and a process of producing a daunorubicin derivative using the transformant. The ketoreductase mutant has an amino acid sequence in which one amino acid residue or two or more amino acid residues selected from the group consisting of amino acids located at positions corresponding to the 42nd, 149th, 153rd, 270th, and 306th amino acids in the amino acid sequence of a ketoreductase (EvaE) from a chlororemomycin-producing bacterium (Amycolatopsis orientalis) are substituted with another amino acid residues.
    Type: Grant
    Filed: May 21, 2010
    Date of Patent: April 15, 2014
    Assignee: Meiji Seika Pharma Co., Ltd.
    Inventors: Fusuke Mazuka, Takayoshi Fukushima, Naomi Sumida, Koji Yanai
  • Publication number: 20130116416
    Abstract: Disclosed are a ketoreductase mutant which can be used for an efficient production of daunorubicin derivatives, a DNA encoding the mutant, a transformant prepared by introducing the DNA thereinto to produce a daunorubicin derivative, and a process of producing a daunorubicin derivative using the transformant. The ketoreductase mutant has an amino acid sequence in which one amino acid residue or two or more amino acid residues selected from the group consisting of amino acids located at positions corresponding to the 42nd, 149th, 153rd, 270th, and 306th amino acids in the amino acid sequence of a ketoreductase (EvaE) from a chlororemomycin-producing bacterium (Amycolatopsis orientalis) are substituted with another amino acid residues.
    Type: Application
    Filed: May 21, 2010
    Publication date: May 9, 2013
    Applicant: MEIJI SEIKA PHARMA, CO., LTD.
    Inventors: Fusuke Mazuka, Takayoshi Fukushima, Naomi Sumida, Koji Yanai
  • Patent number: 8257955
    Abstract: A novel endoglucanase PPCE derived from Penicillium pinophilum, a cellulase preparation containing the endoglucanase PPCE, and a method of treating a cellulose-containing fabric utilizing the endoglucanase PPCE or the cellulase preparation, are disclosed. The endoglucanase PPCE is highly active to a fabric, and has a low optimum temperature and a strongly acidic optimum pH.
    Type: Grant
    Filed: March 12, 2008
    Date of Patent: September 4, 2012
    Assignee: Meiji Seika Pharma Co., Ltd.
    Inventors: Tatsuki Moriya, Akitaka Nakane, Goh Tsujiuchi, Takayoshi Fukushima
  • Publication number: 20110294192
    Abstract: A fusion collagenase in which an affinity tag is added to the carboxyl terminal of a collagenase was expressed as a recombinant protein. It was found that a collagenase having a collagen-binding domain can be selectively collected by purifying the obtained fusion collagenase by affinity chromatography.
    Type: Application
    Filed: November 6, 2009
    Publication date: December 1, 2011
    Applicants: TOHOKU UNIVERSITY, MEIJI SEIKA PHARMA CO., LTD.
    Inventors: Takayoshi Fukushima, Kengo Yokoyama, Koichiro Murashima, Masafumi Goto, Youhei Yamagata
  • Publication number: 20110034405
    Abstract: The present invention relates to novel aminoglycoside antibiotics, a process for producing the same, and pharmaceutical use thereof. More specifically, the present invention relates to compounds represented by formula (I), a process for producing the same, and use of the same as antimicrobial agents. wherein R represents amino or hydroxyl.
    Type: Application
    Filed: December 1, 2008
    Publication date: February 10, 2011
    Inventors: Naomi Sumida, Koji Yanai, Masato Tani, Takayoshi Fukushima, Yasumasa Ota, Shuichi Gomi, Akitaka Nakane
  • Publication number: 20100330646
    Abstract: An object is to efficiently produce thermostable catalase at low cost by expressing it as a recombinant protein in large quantity. A recombinant microorganism capable of efficiently expressing thermostable catalase can be provided by obtaining a DNA necessary for efficiently producing it as a recombinant protein, and the thermostable catalase can be efficiently produced at low cost by cultivating the obtained recombinant microorganism. Hydrogen peroxide can be efficiently decomposed at low cost, even at high temperature, by treating a solution containing hydrogen peroxide with the thermostable catalase of the present invention.
    Type: Application
    Filed: February 18, 2009
    Publication date: December 30, 2010
    Inventors: Kaoru Okakura, Fusuke Mazuka, Takayoshi Fukushima, Koichiro Murashima
  • Publication number: 20100098807
    Abstract: A novel endoglucanase PPCE derived from Penicillium pinophilum, a cellulase preparation containing the endoglucanase PPCE, and a method of treating a cellulose-containing fabric utilizing the endoglucanase PPCE or the cellulase preparation, are disclosed. The endoglucanase PPCE is highly active to a fabric, and has a low optimum temperature and a strongly acidic optimum pH.
    Type: Application
    Filed: March 12, 2008
    Publication date: April 22, 2010
    Applicant: MEIJI SEIKA KAISHA, LTD.
    Inventors: Tatsuki Moriya, Akitaka Nakane, Goh Tsujiuchi, Takayoshi Fukushima